TNP-470 (AGM-1470), a synthetic analog of
fumagillin (6-chloroacetyl-carbamoyloxy-4-(1,2-epoxy-1,5-dimethyl- 4-hexenyl)-5-methoxy-1-oxaspiro [2,5]
octane 1, has been reported to reduce the supply of nutrients to experimental
tumors by inhibiting angiogenesis. In this study, we investigated anti-
tumor activity of
TNP-470 against human thyroid
anaplastic carcinoma with a view to developing a new treatment for this thyroid
tumor. A transplantable
tumor was established from thyroid
anaplastic carcinoma of a 78-year-old woman, as a xenograft in nude mice (BALB/c, nu/nu, male). This transplantable
tumor, with
chromosomal abnormality was shown to be non-functional in excretory
hormones and to preserve morphological characteristics of the original anaplastic
tumor tissue.
TNP-470 was given at a dose of 50 mg/kg b.w. to nude mice transplanted with human thyroid
anaplastic carcinoma by different routes of administration: intratumoral, peritumoral, subcutaneous and intraperitoneal. Intratumoral and peritumoral administration were effective, and especially the
TNP-470 administered by the former route completely inhibited
tumor growth. Immunohistochemical analysis using anti-
factor VIII antibody revealed the density of microvessels to be significantly decreased by local administration of
TNP-470 (intratumoral administration, 7.8 +/- 2.9/mm2, control, 27.0 +/- 6.3/mm2; peritumoral administration, 9.7 +/- 2.6/mm2, control, 21.1 +/- 5.1/mm2). Our findings suggested the possibility of clinical application of
TNP-470 to control the growth of human
anaplastic thyroid carcinoma.